Financial Insights Inc. Buys 344 Shares of Johnson & Johnson $JNJ

Financial Insights Inc. lifted its position in Johnson & Johnson (NYSE:JNJ) by 9.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,065 shares of the company’s stock after buying an additional 344 shares during the quarter. Financial Insights Inc.’s holdings in Johnson & Johnson were worth $621,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of JNJ. Highline Wealth Partners LLC boosted its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter valued at $48,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson in the 1st quarter worth about $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 0.2%

Shares of JNJ opened at $188.23 on Tuesday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $189.92. The firm has a market cap of $453.32 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 2.40 and a beta of 0.40. The firm has a 50 day moving average price of $176.62 and a 200-day moving average price of $163.00. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. UBS Group set a $198.00 price target on Johnson & Johnson in a research report on Friday. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Finally, HSBC upped their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $189.12.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.